Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
RESEARCH TOOLSreports
Holding CLRB?
Track your performance easily
CLRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $4.45
Previous CloseN/A
Volume1.30M
Average Volume (3M)4.50M
Market Cap
$10.00M
Enterprise Value$65.43M
Total Cash (Recent Filing)$11.44M
Total Debt (Recent Filing)$5.25K
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 04, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding41,269,830
10 Day Avg. Volume3,763,843
30 Day Avg. Volume4,498,357
Standard Deviation0.23
R-Squared0.06
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap6.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$7.00Price Target Upside2816.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Cellectar Biosciences News
PremiumCompany Announcements
Cellectar Biosciences Strategic Shift and Workforce Reduction
Bulls Say, Bears Say
Bulls Say
Clinical SuccessCellectar reported the full data set from its pivotal CLOVER WaM P2b study, demonstrating a major response rate of 56.4%, which exceeds the 20% protocol stat hurdle.
Financial StrengthThe company has $34M in cash (above the market cap of ~$10M) and with reduced opex, should have runway into late 2025 and paths forward with earlier-stage assets on what is viewed as a de-risked PDC platform.
Growth OpportunitiesThe radiopharma space is described as active with new opportunities ahead, suggesting potential growth for Cellectar Biosciences.
Bears Say
Company OutlookThe price target for Cellectar Biosciences has been lowered to $1, which could imply challenges or adjustments in the company's outlook.
Financial PerformanceCellectar reported 3Q24 results with a net loss of ($14.6M) and ended the period with $34.3M in cash on the balance sheet.
Regulatory ChallengesCellectar announced that after discussions with FDA, the agency is requiring a confirmatory study to support accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia (WM).
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $0.22 and its highest was $4.45 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $10.00M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Nov 18, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.07.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.35.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 41,269,830 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -4.839%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
---
Company Description
Cellectar Biosciences
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.
---
CLRB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showcased significant progress in clinical trials and financial stability, with promising market opportunities for iopofosine I 131. However, challenges such as the NDA submission delay and increased expenses were acknowledged. The company's extensive pipeline development and strategic collaborations highlight a forward-looking growth strategy, despite regulatory hurdles.Read More>---
CLRB Stock 12 Month Forecast
Average Price Target
$7.00
▲(2816.67% Upside)
Technical Analysis
Best Analysts Covering CLRB
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-10.04%
reiterated a buy rating 29 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -10.04% per trade.
---